Branched Cell-Penetrating Peptides Improve Oral Insulin Delivery Through Intestinal Walls

Branching cell-penetrating peptides (penetratin and penetramax) into dimer and trimer structures significantly increased their ability to enhance transepithelial permeation of insulin and other cargo molecules across Caco-2 cell monolayers. The enhancement correlated with the degree of branching — trimers outperformed dimers, which outperformed linear forms. The mechanism involved immediate and reversible effects on cell monolayer integrity and cytoskeletal alterations, consistent with paracellular transport. In vivo pharmacokinetic studies in rats confirmed that dimeric penetramax enhanced intestinal insulin delivery compared to linear penetramax.

Combined in vitro and in vivo study. Linear, dimer, and trimer versions of penetratin and penetramax were synthesized and tested using Caco-2 cell culture models for transepithelial permeation of insulin, dextran, mannitol, and metoprolol. Cell monolayer integrity and cytoskeletal changes were assessed. In vivo pharmacokinetic studies in rats evaluated dimeric penetramax as an insulin carrier, with histological assessment of intestinal tissue safety.

Oral insulin has been a goal of diabetes research for decades, but the intestinal barrier has been the primary obstacle. Cell-penetrating peptides are among the most promising carriers, and this study shows that a simple structural modification — branching into dimers and trimers — dramatically increases their delivery potency. The reversibility of the effects on intestinal cells is also encouraging for safety.

Cell-penetrating peptides represent one of several approaches being pursued for oral macromolecular drug delivery, alongside nanoparticles, intestinal patches, and permeation enhancers. The branching strategy demonstrated here could potentially be applied to other peptide carriers and other biopharmaceutical cargos beyond insulin — including GLP-1 agonists, growth hormone, and monoclonal antibody fragments — expanding the toolkit for oral biologic delivery.

Caco-2 cell models, while standard, do not fully replicate the complexity of the human intestine (mucus layer, immune cells, variable conditions). Only dimeric penetramax was tested in vivo, not the trimer variants. Long-term safety of repeated dosing with branched peptide carriers was not assessed. Specific blood glucose reduction data or bioavailability percentages are not provided in the abstract.